Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Rodrigues

Showing results (11-20 of 199) with videos related to

Pageof 20
Sort By:
Bulletin Du Cancer|November 10, 2020
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|September 6, 2025
[Durvalumab and Olaparib Combination - First-line metastatic endometrial cancer]Annabelle Sabouret, Manuel Rodrigues
Bulletin Du Cancer|May 10, 2025
[Pembrolizumab or dostarlimab in association to chemotherapy in advanced endometrial cancer]Pierre Grassi, Manuel Rodrigues
Scientific Reports|July 1, 2026
Impact of feature engineering on predicting non-contact football injuriesManuel Rodrigues, Rui Silva
Bulletin Du Cancer|October 22, 2021
[The AMMs review, assessment after one year of existence]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|September 11, 2024
[Rucaparib in maintenance in patients with newly diagnosed ovarian cancer]Lucie Houdou, Manuel Rodrigues
Bulletin Du Cancer|September 13, 2025
[Pembrolizumab with chemoradiotherapy in high risk locally advanced cervical cancer]Mathilde Haberstich, Manuel Rodrigues
Bulletin Du Cancer|May 17, 2021
[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer]Maxime Galienne, Manuel Rodrigues
Bulletin Du Cancer|December 28, 2025
[Tisotumab Vedotin - Metastatic or recurrent cervical cancer as second-line therapy]Marine Bletsas, Manuel Rodrigues
Bulletin Du Cancer|March 1, 2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]Matthieu Delaye, Manuel Rodrigues
Pageof 20

Showing results (11-20 of 199) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|November 10, 2020
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|September 6, 2025
[Durvalumab and Olaparib Combination - First-line metastatic endometrial cancer]Annabelle Sabouret, Manuel Rodrigues
Bulletin Du Cancer|May 10, 2025
[Pembrolizumab or dostarlimab in association to chemotherapy in advanced endometrial cancer]Pierre Grassi, Manuel Rodrigues
Scientific Reports|July 1, 2026
Impact of feature engineering on predicting non-contact football injuriesManuel Rodrigues, Rui Silva
Bulletin Du Cancer|October 22, 2021
[The AMMs review, assessment after one year of existence]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|September 11, 2024
[Rucaparib in maintenance in patients with newly diagnosed ovarian cancer]Lucie Houdou, Manuel Rodrigues
Bulletin Du Cancer|September 13, 2025
[Pembrolizumab with chemoradiotherapy in high risk locally advanced cervical cancer]Mathilde Haberstich, Manuel Rodrigues
Bulletin Du Cancer|May 17, 2021
[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer]Maxime Galienne, Manuel Rodrigues
Bulletin Du Cancer|December 28, 2025
[Tisotumab Vedotin - Metastatic or recurrent cervical cancer as second-line therapy]Marine Bletsas, Manuel Rodrigues
Bulletin Du Cancer|March 1, 2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]Matthieu Delaye, Manuel Rodrigues
Pageof 20